Clinical trial · Observational
Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator
Retrospective Case Review - Clinical Evaluation of the Interlace Medical 1st Generation Hysteroscopic Morcellator
NCT01026805CI-TRIAL-00008528completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study assesses the effectiveness of intrauterine fibroid and polyp removal using the Interlace Medical 1st generation hysteroscopic morcellator device based on a retrospective review of medical records of women who have been treated with the device.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Abnormal Uterine Bleeding | — | UNRESOLVED | — |
| Infertility | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interlace Medical 1st Generation Hysteroscopic Morcellator | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Hysteroscopic Morcellator
- description
- 11 women previously receiving hysteroscopic myomectomy or polypectomy using the hysteroscopic morcellator device.
- interventionNames
- Device: Interlace Medical 1st Generation Hysteroscopic Morcellator
Primary outcomes (1)
- measure
- Percentage of Tissue Removed
- timeFrame
- immediately post-treatment
- description
- mean percentage of polyp and fibroid tissue removed, as measured on post-treatment hysteroscopic imaging. Images were obtained immediately post treatment, before the subject left the surgical suite.
Secondary outcomes (6)
- measure
- Treatment Time Per Patient
- timeFrame
- at time of treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * female * at least 18 years old * treated for intra-uterine submucosal fibroids (Type 0 or 1 myomas and/or polyps using the Interlace 1st generation morcellator device. Exclusion Criteria: * none
References
Publications (0)
Data not yet available
No reference posted for this study.